EMA Turns Down 3 Therapies Across Oncology, Transplantation

Published Date: 30 Jun 2026

Tacquell, Yartemlea, and Xervyteg failed to secure positive CHMP recommendations after EMA identified major concerns with efficacy, safety, and data interpretability.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More men with prostate cancer are avoiding unnecessary surgery

2.

Even when they are not paying attention, children are still learning.

3.

FDA Approves New Bladder Cancer First-Line Standard of Care.

4.

"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.

5.

AI is useful in low-resource areas for triaging breast masses.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot